Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up.
Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up.
复制标题
DOI：
10.1016/j.jaac.2020.07.906
复制
发表时间：
2021-07
影响因子：
13.3
通讯作者：
Neurofeedback Collaborative Group
中科院分区：
文献类型：
--
作者：
Neurofeedback Collaborative Group
确定theta/beta-ratio（TBR）脑电图生物反馈（Neurofeatback，nf）是否对非特异性益处的注意力缺陷/多动症（ADHD）具有特定的影响。
在2个站点的随机临床试验中，有144名儿童7-10岁，被诊断为中度/重度ADHD和THETA/beta-Ratio（TBR）≥4.5≥4.5是随机的3：2，以进行tbr训练，以审议持续时间和同等效力的持续时间，以进行相等的持续时间，以进行142次参与。治疗是通过现场统计学家的共同投资者进行了互联网，由培训师/治疗师进行了98.7％的态度，NF专家监视器的主要结果是父母效率的不足。
盲人是出色的。 NF和54％的对照（p = .36）。
这项研究不支持在治疗端或13个月的随访中有意的TBR NF的特定效果。
ADHD神经反馈的双盲位随机试验；
To determine whether theta/beta-ratio (TBR) electroencephalographic biofeedback (neurofeedback, NF) has a specific effect on attention-deficit/hyperactivity disorder (ADHD) beyond nonspecific benefit. In a 2-site double-blind randomized clinical trial, 144 children age 7–10 with rigorously diagnosed moderate/severe ADHD and theta/beta-ratio (TBR)≥4.5 were randomized 3:2 to deliberate TBR downtraining vs. a control of equal duration, intensity, and appearance. Two early dropouts left 142 for modified intent-to-treat analysis. The control utilized pre-recorded EEGs with participant’s artifacts superimposed. Treatment was programmed via internet by an off-site statistician-guided co-investigator. Fidelity was 98.7% by trainers/therapists, 93.2% by NF expert monitor. Primary outcome was parent- and teacher-rated inattention; analysis was mixed-effects regression. Because expense and effort of NF can be justified only by enduring benefit, follow-ups were integrated. Blinding was excellent. While both groups showed significant improvement (p<0.001, d=1.5) in parent/teacher rated inattention from baseline to treatment-end and 13-month follow-up, NF was not significantly superior to the control condition at either time point on this primary outcome (d=0.01, p=0.965 at treatment end; d=0.23, p=.412 at 13-month follow-up). Responders (CGI-I=1–2) were 61% of NF and 54% of Controls (p=.36). Adverse events were distributed proportionally between treatments. 13–month follow-up found nonsignificant improvement from treatment end for NF (d=0.1), with mild deterioration for controls (d= −0.07). NF required significantly less medication at follow-up (p=.012). This study does not support a specific effect of deliberate TBR NF at either treatment end or 13-month follow-up. Participants will be reassessed at 25-month follow-up. Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD; https://clinicaltrials.gov/; NCT02251743.
登录
查看更多内容
影响因子：
2.4
作者：
Monastra, VJ;Lubar, JF;Linden, M
通讯作者：
Linden, M
影响因子：
3
作者：
OMIZO, MM;MICHAEL, WB
通讯作者：
MICHAEL, WB
DOI：
10.1097/chi.0b013e31819c23d0
发表时间：
2009-05
影响因子：
13.3
作者：
Molina BSG;Hinshaw SP;Swanson JM;Arnold LE;Vitiello B;Jensen PS;Epstein JN;Hoza B;Hechtman L;Abikoff HB;Elliott GR;Greenhill LL;Newcorn JH;Wells KC;Wigal T;Gibbons RD;Hur K;Houck PR;MTA Cooperative Group
通讯作者：
MTA Cooperative Group
影响因子：
6.4
作者：
Geladé K;Bink M;Janssen TW;van Mourik R;Maras A;Oosterlaan J
通讯作者：
Oosterlaan J
影响因子：
3
作者：
Arnold LE;Lofthouse N;Hersch S;Pan X;Hurt E;Bates B;Kassouf K;Moone S;Grantier C
通讯作者：
Grantier C